A Preventative Adenoviral-Based H5N1 Influenza Vaccine

基于腺病毒的预防性 H5N1 流感疫苗

• 批准号: 7077267
• 负责人: ANDREA GAMBOTTO
• 金额: $ 96.24万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-08-01 至 2008-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7077267
• 关键词: antigens; human; influenza vaccines; model; pharmacology; southeast Asia

DESCRIPTION (provided by applicant): Wild waterfowl, the natural hosts of all known influenza A viruses, are the source of viruses which cause sporadic outbreaks of highly fatal disease in domestic poultry. Since 1997, highly pathogenic (HP) avian influenza A H5N1 viruses have caused a series of outbreaks in Hong Kong, and most recently in 9 other Asian countries. As human exposure to and infection with H5N1 viruses continues to increase, so too does the likelihood of the generation of an avian-human reassortant virus which may transmit efficiently within the human population which lacks HA-specific immunity to H5N1 viruses. In 1997, HPAl H5N1 in Hong Kong resulted in transmission from poultry to humans, resulting in 18 infected people and six deaths. In 2003- 2005, extensive outbreaks of highly pathogenic avian influenza A (H5N1) occurred in several Asian countries (Cambodia, China, Indonesia, Japan, Laos, South Korea, Thailand and Vietnam, North Korea), resulting in 17 human cases in Thailand and 27 in Vietnam and 3 in Cambodia; there were 51 reported deaths. H5N1 infections in family clusters have raised the possibility of human-to-human transmission of H5N1 virus. We have recently developed an adenoviral-based influenza vaccine encoding the hemagglutinin (HA) antigen of the A/Vietnam/1203/2004 (H5N1) strain isolated during the 2003-2005 lethal human outbreak. Vaccinated mice and chickens had broad virus-specific cellular and humoral immunity and were fully protected from a lethal intranasal H5N1 challenge, whereas all control animals died within few days. Hence, a centralized and integrated clinical vaccine testing will be proposed.

描述（由申请人提供）：野生水禽是所有已知甲型流感病毒的天然宿主，是导致家禽零星爆发高度致命疾病的病毒来源。自 1997 年以来，高致病性 (HP) 甲型 H5N1 禽流感病毒在香港以及最近在其他 9 个亚洲国家引发了一系列疫情。随着人类接触和感染 H5N1 病毒的不断增加，产生禽-人重配病毒的可能性也在增加，这种病毒可以在缺乏针对 H5N1 病毒的 HA 特异性免疫力的人群中有效传播。 1997年，香港发生H5N1禽流感病毒，导致18人感染，6人死亡。 2003年至2005年，多个亚洲国家（柬埔寨、中国、印度尼西亚、日本、老挝、韩国、泰国和越南、朝鲜）爆发高致病性甲型H5N1禽流感，造成泰国17人感染病例越南27个，柬埔寨3个；据报道有51人死亡。家庭聚集性H5N1感染增加了H5N1病毒人传人的可能性。我们最近开发了一种基于腺病毒的流感疫苗，编码 2003-2005 年致命人类疫情期间分离出的 A/Vietnam/1203/2004 (H5N1) 毒株的血凝素 (HA) 抗原。接种疫苗的小鼠和鸡具有广泛的病毒特异性细胞和体液免疫力，并且完全免受致命的鼻内 H5N1 攻击，而所有对照动物都在几天内死亡。因此，将提出集中、综合的临床疫苗测试。